MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Market Concentration and Competitive Landscape

Close-monitor your Competitor's Move, Request sample copy

There is a growing trend in the oncology field towards more personalized and precision medicine based on a patient’s specific disease characteristics and risk factors. Advanced MRD technologies allow the quantitative assessment of the tumor burden right down to a single cancer cell. Key opinion leaders note that MRD status is already used to personalize post-remission therapy decisions in some blood cancer types. For example, in acute myeloid leukemia, an MRD negative status may allow stopping further treatment whereas MRD positivity could warrant a stem cell transplant. Researchers are also exploring use of MRD for predicting survival outcomes and tailoring surveillance schedules accordingly. As clinical studies establish MRD as a reliable biomarker, its use for personalized risk stratification and subsequent personalization of treatment regimens is expected to increase tremendously. This drives the need for the wider adoption of sensitive and standardized MRD testing methods across the continuum of care.

• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd
• Guardant Health, Inc.
• Adaptive Biotechnologies
• Invitae Corporation
• ASURAGEN, INC.
• Invivoscribe, Inc. 
• Laboratory Corporation of America Holdings
• Natera, Inc.
• Sysmex Inostics, Inc.
• Amgen Inc.
• FOUNDATION MEDICINE, INC.
• Sebia
• Myriad Genetics, Inc.